Tag: M.W:100-200

21169-71-1, Isoxazole-5-carboxylic acid is a Isoxazoles compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: Compounds were synthesized in solution phase using Boc-protected amino acids on 100-200mg scale. Firstly, the amino acid (1.2-1.5equiv) was activated with HBTU (1.5equiv) and DIPEA (1.5equiv) as 0.2-0.5M solution in DMF for 10min. Then the solution was added to an amino group bearing C-terminal moiety (R1R2NH) and the mixture was stirred for a minimum of 1h at room temperature. The reaction mixture was diluted with EtOAc and washed with saturated NaHCO3 (2¡Á). The organic extracts were dried over MgSO4, filtered and evaporated in vacuo. The crude product was then treated with 20% TFA in DCM and stirred for 1-2h to remove the Boc group. TFA was removed by evaporating the reaction mixture under a stream of N2. The residue was dissolved in DCM and washed with saturated NaHCO3 (2¡Á). DCM phase was dried with MgSO4, filtered and evaporated in vacuo. Subsequent N-Boc-amino acids and amines were sequentially coupled under the same conditions. Each coupling reaction was monitored by ESMS, with most reactions going to completion overnight. All final compounds were purified on rpHPLC (97% by analytical HPLC) and fully characterized by NMR and HRMS (yields between 30% and 40%).

21169-71-1, As the paragraph descriping shows that 21169-71-1 is playing an increasingly important role.

Reference£º
Article; Yau, Mei-Kwan; Liu, Ligong; Lim, Junxian; Lohman, Rink-Jan; Cotterell, Adam J.; Suen, Jacky Y.; Vesey, David A.; Reid, Robert C.; Fairlie, David P.; Bioorganic and Medicinal Chemistry Letters; vol. 26; 3; (2016); p. 986 – 991;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.3209-71-0,Isoxazole-3-carboxylic Acid,as a common compound, the synthetic route is as follows.

Solid NaH (60% wt in oil) (425 mg, 10.6 mmol) was added to a THF solution (50 mL) of isoxazole-3-carboxylic acid (1.0 g, 8.8 mmol). After 15 min neat ethylchloroformate (1.0 mL, 10.6 mmol) was added. After 45 min a 7 N ammonia solution in MeOH (5.0 mL, 35 mmol) was added. After 30 min the mixture was diluted with EtOAc washed with water and brine, dried (Na2SO4) and dry packed onto silica gel. Column chromatography gave 600 mg of the title compound., 3209-71-0

3209-71-0 Isoxazole-3-carboxylic Acid 11286453, aIsoxazoles compound, is more and more widely used in various fields.

Reference£º
Patent; JANSSEN PHARMACEUTICA NV; BARBAY, J., Kent; CHAKRAVARTY, Devraj; SHOOK, Brian, Christopher; WANG, Aihua; WO2010/45006; (2010); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.21169-71-1,Isoxazole-5-carboxylic acid,as a common compound, the synthetic route is as follows.,21169-71-1

To a flask containing 8-[5-(S)-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-1, 2, 4a, 5-tetrahydropyrazino[2, 1-c] [1, 4]benzoxazine-3(4H)-carboxylic acid phenylmethyl ester (EXAMPLE 1, 150 mg, 0.31 mmol) in methanol (5 mL) and methylene chloride (5 mL) is introduced 10% palladium on carbon (70 mg). The mixture is placed under a hydrogen balloon for 17 hours, filtered through celite, and concentrated in vacuo. The residue is dissolved in pyridine (5 mL) followed by the addition of isoxazole-5-carboxylic acid (40 mg, 0.35 mmol), 4-dimethylaminopyridine (5 mg, 0.04 mmol), and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride(70 mg, 0.35 mmol). The reaction is stirred under an inert atmosphere for 17 hours, diluted with methylene chloride (20 mL), washed with 1N HCl (20 mL) and saline, dried over Na2SO4, concentrated in vacuo and chromatographed on silica gel (230-400 mesh, 100 mL), eluting with chloroform/methanol (97/3). The appropriate fractions are combined (Rf= 0.42, TLC, chloroform/methanol, 90/10) and concentrated in vacuo to give the title compound, HRMS calcd for C21H23N5O6: 441.1648. Found: 441.1658.

The synthetic route of 21169-71-1 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; PHARMACIA & UPJOHN COMPANY; EP874852; (2004); B1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

35166-33-7, 3-Hydroxymethyl-5-methylisoxazole is a Isoxazoles compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

a) 3-(tert-Butyldimethylsilyloxymethyl)-5-methylisoxazole To a chilled (5 C.) solution of 3-hydroxymethyl-5-methylisoxazole (16.8 g, 148 mmol) and tert-butyldimethylsilyl chloride (24.6 g, 163 mmol) in dry methylene chloride (100 mL) was added over 15 minutes a solution of triethylamine (22.7 mL, 163 mmol) in methylene chloride (25 mL). 4-Dimethylaminopyridine (1.81 g, 14.8 mmol) was added and the thick reaction mixture was stirred at room temperature for 48 hours. Water (100 mL) was added and the aqueous layer extracted with methylene chloride (3*). The combined organic phases were washed with brine, dried (MgSO4), filtered through a pad composed of a layer of Florisil and a layer of Silica Gel 60, and concentrated in vacuo. The yellow oil obtained (36.6 g) was purified by chromatography (Silica Gel 60, 2% ethyl acetate in hexanes) to give 27.7 g (81.9%) of pure title compound as a pale yellow oil.

35166-33-7, The synthetic route of 35166-33-7 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Sterling Winthrop Inc.; US5349068; (1994); A;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

14441-90-8, 5-Phenylisoxazole-3-carboxylic acid is a Isoxazoles compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

a solution of 5-phenyl-l,2-oxazole-3-carboxylic acid (850.5 mg, 4.50 mmol, 1.51 eq.) and 2-(3- aminocyclobutyl)ethan-l-ol hydrochloride (452 mg, 2.98 mmol, 1.00 eq.) in dichloromethane (25 mL)was placed in a 100-mL round-bottom flask. HATU (1.368 g, 3.60 mmol, 1.21 eq.) and DIEA (1.161 g, 8.98 mmol, 3.01 eq.) were added to the solution and stirred for 1 hour at room temperature. The resulting solution was diluted with 50 mL of water, extracted with chloromethane (3×30 mL) and the organic layers combined. The resulting mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The crude product was purified by Flash-Prep-HPLC with the following conditions (CombiFlash-1): Column, C18 silica gel; mobile phase, MeCN/H20=55:45 increasing to MeCN/H2O=60:40 within 2 min; Detector, UV 254 nm to give 110 mg (13%) of N-[3-(2-hydroxyethyl)cyclobutyl]-5-phenyl- l,2-oxazole-3-carboxamide as a off-white solid. The isomers were separated by Chiral-Prep- HPLC using the following conditions (Prep-HPLC-009): Column, Repaired IA, 21.2* 150mm, 5um; mobile phase, Hexane and ethanol (hold 20.0% ethanol in 20 min); Detector, UV 254/220 nm. This resulted in 23.8 mg (60%) of 5-phenyl-N-[ ram,-3-(2-hydroxyethyl)cyclobutyl]-l,2- oxazole-3-carboxamide as a white solid and 35.7 mg (70%) of 5-phenyl-N-[cw-3-(2- hydroxyethyl)cyclobutyl]-l,2-oxazole-3-carboxamide as a white solid. iV-iras-3-(2-hydroxyethyl)cyclobutyl)-5-phenylisoxazole-3-carboxamide: [0439] LC-MS: (M+H)+ = 287 [0440] Analytical data: XH NMR (CDC13, 400MHz): delta 7.83-7.81 (m, 2H), 7.54-7.49 (m, 3H), 7.05-7.02 (m, 1H), 6.97 (s, 1H), 4.72-4.67 (m, 1H), 3.73-3.68 (t, J = 10.0Hz, 2H), 2.49- 2.41 (m, 1H), 2.26-2.21 (m, 4H), 1.87-1.81 (m, 2H). [0441] HPLC purity: 99.4% at 254 nm. iV-cis-3-(2-hydroxyethyl)cyclobutyl)-5-phenylisoxazole-3-carboxamide: [0442] LC-MS: (M+H)+ = 287 [0443] Analytical data: XH NMR (CDC13, 400MHz): 7.83-7.80 (m, 2H), 7.54-7.49 (m, 3H), 7.02-6.93 (m, 3H), 4.50-4.44 (m, 1H), 3.67-3.63 (t, J= 8.0Hz, 2H), 2.68-2.62 (m, 2H), 2.22- 2.13 (m, 1H), 1.76-1.66 (m, 4H). [0444] HPLC purity: 99.0% at 254 nm., 14441-90-8

The synthetic route of 14441-90-8 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; PROTEOSTASIS THERAPEUTICS, INC.; BASTOS, Cecilia, M.; MUNOZ, Benito; TAIT, Bradley; (178 pag.)WO2016/115090; (2016); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

2510-36-3, 3,5-Dimethylisoxasole-4-carboxylic acid is a Isoxazoles compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a solution of 3,5-dimethylisoxazole-4-carboxylic acid (58 mg, 2.5 equiv.) in DMF (3 mL) was added D/PEA (202 uL, 7 equiv.), followed by TBTU (160 mg, 3 equiv.). The reaction mixture was stirred at RT for one hour, and then 4-[[4-(lH-pyrrolo[2,3-?]pyridin- 3-yl)-l-piperidyl]sulfonyl]aniline (59 mg, 1 equiv.) was added. The reaction mixture was stirred at RT for 30 min, and at 100 C for 2 h. The reaction mixture was cooled to RT, and the solvent was removed in vacuo. The residue was partitioned betweed EtOAc and water, organic phase was washed with brine, dried over Na2S04, filtered, and the solvent was removed in vacuo to yield the crude product. The crude product was purified by column chromatography, followed by preparative HPLC-MS to yield the expected product (11.5 mg). LCMS: MW (calc’d): 479.5; MS (ES+, m/z): 480.7 [M+H]+., 2510-36-3

As the paragraph descriping shows that 2510-36-3 is playing an increasingly important role.

Reference£º
Patent; E-THERAPEUTICS PLC; JURKOVIC, Mihaela; LANDEK, Ivana Ozimec; POLJAK, Tanja; RO?CIC, Maja; STUBBERFIELD, Colin; VADLAMUDI, Srinivasamurthy; (228 pag.)WO2019/43372; (2019); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.123770-62-7,Ethyl 5-(hydroxymethyl)isoxazole-3-carboxylate,as a common compound, the synthetic route is as follows.

6.5. tert-Butyl 2-(3-carbamoylisoxazol-5-ylmethoxycarbonylamino)-6-azaspiro[3.4]octane-6-carboxylate A solution of 0.304 g (1.51 mmol) of 4-nitrophenyl chloroformate dissolved in 5 mL of 1,2-dichloroethane is added dropwise to a solution containing 0.284 g (1.66 mmol) of ethyl 5-hydroxymethylisoxazole-3-carboxylate and 0.39 g (3.02 mmol) of N,N-diisopropylethylamine in 10 mL of 1,2-dichloroethane, cooled to about 0 C. Stirring is continued at 0 C. for 1 hour and then at room temperature for 1 hour. 0.39 g (3.02 mmol) of N,N-diisopropylethylamine and then 0.34 g (1.51 mmol) of tert-butyl 2-amino-6-azaspiro[3.4]octane-6-carboxylate, prepared in step 6.4., are added. The reaction medium is stirred at 70 C. for 4 hours. It is allowed to cool to room temperature. Water is added to the reaction medium, the aqueous phase is separated out and extracted several times with dichloromethane, the combined organic phases are washed with aqueous sodium hydroxide solution (1N) and then with saturated aqueous ammonium chloride solution and dried over sodium sulfate, and the filtrate is concentrated under reduced pressure. 0.44 g of pure product is thus obtained in the form of an orange oil, which is used without further purification in the following step. LC-MS: M+H=424 1H NMR (DMSO) delta (ppm): 7.80 (broad s, 1H); 6.90 (s, 1H); 5.20 (s, 2H); 4.40 (q, 2H) 4.00 (m, 1H); 3.40-3.10 (m, 4H); 2.30 (m, 2H); 2.00-1.70 (m, 4H); 1.40 (s, 9H); 1.30 (t, 3H)., 123770-62-7

As the paragraph descriping shows that 123770-62-7 is playing an increasingly important role.

Reference£º
Patent; SANOFI; US2011/319381; (2011); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

36958-61-9, 5-(Bromomethyl)-3-methylisoxazole is a Isoxazoles compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

-Benzylsulfanyl-4-chloro-2H-phthalazin-1 -one (500. mg, 1 .65 mmol) in DMF (15 mL) was cooled in an ice bath, treated with sodium hydride (60% w/w) (69.35 mg, 1 .73 mmol), and the resulting mixture was stirred at ambient temperature for 1 h. 5- (Bromometh

36958-61-9, As the paragraph descriping shows that 36958-61-9 is playing an increasingly important role.

Reference£º
Patent; CANCER RESEARCH TECHNOLOGY LIMITED; MCGONAGLE, Alison E.; JORDAN, Allan; WASZKOWYCZ, Bohdan; HUTTON, Colin; WADDELL, Ian; HITCHIN, James R.; SMITH, Kate Mary; HAMILTON, Niall M.; (497 pag.)WO2016/92326; (2016); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.42831-50-5,5-Methylisoxazole-4-carboxylic acid,as a common compound, the synthetic route is as follows.,42831-50-5

(iv) 5-Methylisoxazol-4-yl carbonyl chloride Thionyl chloride (118 g) was added to 5-methylisoxazol-4-yl carboxylic acid (42 g) and stirred at room temperature as dimethylformamide (0.2 ml) was added. The solution was heated under reflux for 2 hours with stirring. Excess thionyl chloride was removed in vacuo at 50 C., then the residue was distilled through a 15 cm Vigreaux column at reduced pressure to give an oil, b.p. 32-34 C./0.1 mm Hg.

The synthetic route of 42831-50-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Lilly Industries Limited; US4892963; (1990); A;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

36958-61-9, 5-(Bromomethyl)-3-methylisoxazole is a Isoxazoles compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Preparation 67: 6-(5-chloro-2-{[(2,4-dimethoxyphenyl)methyl](oxan-4-yl)amino}pyrimidin- 4-yl)-2-[(3-methy 1-1 ,2-oxazol-5-yl)methyl]-2,3-dihydro-1 H-isoindol-1 -one (1591) (1592) A stirred suspension of 6-(5-chloro-2-{[(2,4-dimethoxyphenyl)methyl](oxan-4-yl)arnino}pyrimidin- 4-yl)-2,3-dihydro-1 H-isoindol-1-one (100 mg, 0.20 mmol) in THF (2 mL) was cooled to -78 C and treated with a lithium bis(trimethylsilyl)amide (1 M in THF, 0.3 mL, 0.3 mmol). The resulting suspension was stirred for 15 min before 5-(bromomethyl)-3-methylisoxazole (53 mg, 0.30 mmol) was added. The resulting suspension was allowed to reach RT and the resulting orange solution was stirred for 18 h. The mixture was treated at room temperature with more 5- (bromomethyl)-3-methylisoxazole (53 mg, 0.30 mmol) and stirred for 5 h. Lithium (1593) bis(trimethylsilyl)amide (1 M in THF, 0.15 mL, 0.15 mmol) was added and the mixture was stirred for 15 min before 5-(bromomethyl)-3-methylisoxazole (53 mg, 0.30 mmol) was added and the mixture stirred for 3 days. Brine (5 mL) was added and the mixture was extracted with ethyl acetate (3×5 mL). The combined organic phases were washed with brine (5 mL), dried (Na2S04) and concentrated. Purification by chromatography (S1O2, 10-100% ethyl acetate in iso-hexane) gave the title compound (79 mg, 67%) as a yellow foam. LC-MS: [M+H]+ =590., 36958-61-9

36958-61-9 5-(Bromomethyl)-3-methylisoxazole 10607354, aIsoxazoles compound, is more and more widely used in various fields.

Reference£º
Patent; OTSUKA PHARMACEUTICAL CO., LTD.; BERDINI, Valerio; BUCK, Ildiko Maria; DAY, James Edward Harvey; GRIFFITHS-JONES, Charlotte Mary; HEIGHTMAN, Thomas Daniel; HOWARD, Steven; MURRAY, Christopher William; NORTON, David; O’REILLY, Marc; WOOLFORD, Alison Jo-Anne; COOKE, Michael Liam; COUSIN, David; ONIONS, Stuart Thomas; SHANNON, Jonathan Martin; WATTS, John Paul; (867 pag.)WO2017/68412; (2017); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem